Abstract 48P
Background
Deciphering the role of the adaptive immune system is key to fully realize the potential of immuno-oncology in CCA. TILs are components of the immune microenvironment with a prognostic value across cancer types yet understudied in CCA.
Methods
Tissue blocks from 70 CCA pts undergoing radical surgery between 2013-2023 at the University Hospital of Modena were retrieved. IHC for CD4, CD8 and Foxp3 was performed for the intratumoural (i) and stromal (s) compartment. TILs were recorded as continuous variables and dichotomized to the median. Both bulk RNAseq and spatial trascriptomics were applied through TempO-seq and GeoMx. Correlation analyses and survival models were performed using IBM SPSS Statistics version 25.0.
Results
55% and 42% pts had iCD4+high and sCD4+high CCAs, 54% and 27% of them had iCD8+high and sCD8+high CCAs, and 28% and 34% of them had iFoxp3+high and sFoxp3+high CCAs. iCD4+ high CCAs were associated with pN0 status and a significantly longer RFS than CD4+ low cases (p=0.02). Contrariwise, pts with increased iCD8+ T cell density had significantly shorter RFS than iCD8+ T cells low tumours (p=0.05). iCD4+ T cells together with ECOG PS, nodal status, and adjuvant chemotherapy were independent predictors of outcome. Among iCD4+ high cases, adjuvant chemotherapy significantly prolonged survival compared to observation alone (p=0.01), while no difference was seen within the iCD4+ low subgroup (p=0.06). Compared to CCAs with lower TILs infiltration, iCD4+ high and iCD8+high subsets exhibited 342 and 393 differentially expressed genes, enriched in metabolic, beta-catenin and KRAS pathways and interferon alfa, DNA repair and VEGF networks, respectively.
Conclusions
More than 50% of CCAs displayed high intratumour infiltration of CD4+ and CD8+ TILs, which defined transcriptionally distinct entities with different clinical implications. Interestingly, higher iCD4+ density predicted a favourable prognosis and a benefit from adjuvant chemotherapy in our cohort. These preliminary findings prompt future studies diving into the biomarker potential of TILs in CCA.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Azienda Ospedaliero Universitaria di Modena.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
242P - Clinical outcomes in patients (pts) with HR+/HER2− early breast cancer (EBC) by prior systemic treatment (tx): A subgroup analysis of the NATALEE trial
Presenter: Nicholas McAndrew
Session: Poster session 13
243P - Prognosis of patients with hormone receptor-positive/HER2-negative early breast cancer according to monarchE and NATALEE trials risk categories: Patient-level analysis of Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomised trials
Presenter: Luca Arecco
Session: Poster session 13
244P - Efficacy and safety of dalpiciclib, exemestane, and goserelin as neoadjuvant therapy in premenopausal HR-positive, HER2-negative breast cancer patients: A phase II clinical trial
Presenter: Yang Zhengjun
Session: Poster session 13
245P - Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis
Presenter: Paolo Tarantino
Session: Poster session 13
246P - Axillary management and outcomes after neoadjuvant endocrine therapy in the randomized PELOPS trial
Presenter: Anna C. Weiss
Session: Poster session 13
247P - Concurrent versus sequential adjuvant chemoradiotherapy in early-stage breast cancer: A systematic review and meta-analysis
Presenter: Luiz Felipe de Almeida
Session: Poster session 13
248P - Impact of unilateral mastectomy with or without immediate breast reconstruction on vertebral alignment
Presenter: Jong-Ho Cheun
Session: Poster session 13
249P - Neoadjuvant chemotherapy in inflammatory breast cancer: A meta-analysis of 10 trials of the German Breast Group (GBG)
Presenter: Laura Michel
Session: Poster session 13
250P - Development and validation of a 19-feature classifier that predicts response to neoadjuvant trastuzumab emtansine (T-DM1) in breast cancer patients
Presenter: Fresia Pareja
Session: Poster session 13